Physician profile
Jason Ohlstein
NPI 1164871505
$10,625.10
in general payments reported to CMS, 2019-2025
33 companies · $3,495 in 2025
The $3,495 reported for 2025 was more than what 94% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $301 · 2020: $309 · 2021: $1,108 · 2022: $2,415 · 2023: $1,328 · 2024: $1,669 · 2025: $3,495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,326 · Travel and Lodging: $1,166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,325.89 |
| Travel and Lodging | $1,166.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $4,097.40 | 2021-2025 | Inspire |
| Medical Device Business Services, INC. | $1,277.41 | 2020-2022 | |
| Neurent Medical Limited | $1,156.07 | 2022-2024 | Neuromark Device, Neuromark Radiofrequency Console |
| Medtronic, INC. | $633.79 | 2021-2025 | Pteye Parathyroid Detection System, Nim Vital |
| Stryker Corporation | $413.01 | 2019-2022 | |
| Optinose US, INC. | $401.51 | 2021-2025 | |
| Acera Surgical, INC. | $396.93 | 2025 | Restrata Wound Matrix |
| Aerin Medical INC. | $333.02 | 2022-2025 | |
| Genzyme Corporation | $281.15 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $230.22 | 2021-2024 | Dupixent |
| Glaxosmithkline, LLC. | $218.81 | 2021-2023 | Nucala |
| Depuy Synthes Sales INC. | $200.28 | 2020-2024 | Trumatch |
| Intersect Ent, INC. | $126.23 | 2022 | |
| Amgen INC. | $119.71 | 2021 | |
| Aimmune Therapeutics, INC. | $81.79 | 2022-2023 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cochlear Americas | $72.18 | 2025 | Osia Osi300 Implant, Baha, Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode |
| Tactile Systems Technology INC | $64.14 | 2022-2025 | Flexitouch Plus, Nimbl |
| Acclarent, INC | $57.56 | 2022 | |
| Zimmer Biomet Holdings, INC. | $51.17 | 2019 | |
| Csl Behring | $49.64 | 2021-2022 | |
| Organogenesis INC. | $47.69 | 2023 | Puraply |
| Hologic Sales and Service, LLC | $47.54 | 2022 | |
| Kerecis Limited | $47.42 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Medtronic USA, INC. | $36.85 | 2019-2020 | |
| Genentech USA, INC. | $33.05 | 2023 | Xolair |
| Rayner Intraocular Lenses Limited | $31.44 | 2023 | Omidria, Rayone Spheric, Rayone Emv |
| Incyte Corporation | $27.82 | 2023 | Opzelura |
| Olympus Corporation of The Americas | $20.25 | 2023 | Olympus |
| Phadia US INC. | $18.75 | 2023 | Immunocap |
| Paratek Pharmaceuticals, INC. | $14.54 | 2025 | Xhance |
| Biocryst US Sales Co., LLC | $14.37 | 2023 | Orladeyo |
| Merck Sharp & Dohme LLC | $11.68 | 2021 | |
| Bio Products Laboratory USA, INC. | $11.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Ohlstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.